Form 8-K - Current report:
SEC Accession No. 0000950170-24-089278
Filing Date
2024-08-01
Accepted
2024-08-01 16:10:10
Documents
13
Period of Report
2024-08-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rgnx-20240801.htm   iXBRL 8-K 39718
2 EX-99.1 rgnx-ex99_1.htm EX-99.1 247611
3 GRAPHIC img101737798_0.jpg GRAPHIC 14335
  Complete submission text file 0000950170-24-089278.txt   437029

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rgnx-20240801.xsd EX-101.SCH 25017
15 EXTRACTED XBRL INSTANCE DOCUMENT rgnx-20240801_htm.xml XML 4739
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Filer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37553 | Film No.: 241166709
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)